Is ANI Pharmaceuticals (ANIP) overvalued or fairly valued?

MarketChacha shows ANI Pharmaceuticals's valuation in context — a trailing P/E of about 22.4, a forward P/E of about 7.2, a price-to-book of about 2.9 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does ANI Pharmaceuticals's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (4.68×) from reported figures — education, not a rating.

What is ANI Pharmaceuticals's revenue?

ANI Pharmaceuticals reported revenue of $883.4M for FY2025, with net profit of $78.3M, per official filings.

What is the share price of ANI Pharmaceuticals (ANIP)?

ANI Pharmaceuticals last traded at $77.51 (-2.1% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

ANI Pharmaceuticals

ANIP · NYSE · Healthcare · United States

$77.51-2.1%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:28 PM

Snapshot

TickerANIP

ExchangeNYSE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

CountryUnited States

Employees970

HeadquartersBaudette, United States

Market cap$1.8B

P/E (TTM)22.4

P/B2.9

Volume104.96K

Websitewww.anipharmaceuticals.com

Filings tracked5

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Profile as reported by Yahoo Finance.

Who owns it

Insiders5.5%
Institutions94.5%
Public & other0.0%

387 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.12.09%
Vanguard Capital Management LLC3.62%
Soleus Capital Management, L.P.3.61%
State Street Corporation3.39%
Tang Capital Management, LLC3.11%
Goldentree Asset Management LP2.94%
Deep Track Capital, Lp2.64%
Millennium Management Llc2.60%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion4.68×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend3.9% → 8.9%

Margin has expanded by about 5.0 points — the business is getting more profitable.

Growth qualityrev 35% · PAT 104%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $297.5M · EPS 2.51

Est. earnings growth +23.1%

Next fiscal year

Rev $1.2B · EPS 10.76

Est. earnings growth +14.2%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$62.6152-wk range$99.50

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$1.8B

Day change

-2.1%

P/E (TTM)

22.4

Fwd P/E

7.2

P/B

2.9

Beta

0.43

Revenue (FY2025)

$883.4M

Net margin

8.9%

ROE

14.5%

Revenue CAGR (2y)

+34.7%

Profit CAGR (2y)

+104.2%

EPS (FY2025)

3.32

Net profit (FY2025)

$78.3M

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about ANIP

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$883.4M	$78.3M	3.32	8.9%	14.5%
FY2024	$614.4M	$-18.5M	-1.04	-3.0%	-4.6%
FY2023	$486.8M	$18.8M	0.85	3.9%	4.3%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$237.5M	$29.5M	1.28	12.4%
2025Q3	$227.8M	$26.6M	1.13	11.7%
2025Q2	$211.4M	$8.5M	0.36	4.0%
2025Q1	$197.1M	$15.7M	0.69	8.0%
2024Q3	$148.3M	$-24.2M	-1.27	-16.3%
2024Q2	$138.0M	$-2.3M	-0.14	-1.7%
2024Q1	$137.4M	$18.2M	0.82	13.2%
2023Q3	$131.8M	$9.9M	0.45	7.5%
2023Q2	$116.5M	$6.2M	0.29	5.4%
2023Q1	$106.8M	$1.4M	0.06	1.3%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Executive/director change, Shareholder vote results, Exhibits
SEC5/21/2026material
8-K — Reg FD disclosure, Exhibits
SEC5/13/2026material
8-K — Results of operations, Exhibits
SEC5/8/2026material
10-Q filing
SEC5/8/2026
8-K — Auditor change, Exhibits
SEC4/7/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.